financetom
Business
financetom
/
Business
/
Why Oragenics (OGEN) Stock Is Getting Hammered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Oragenics (OGEN) Stock Is Getting Hammered
Sep 6, 2024 12:28 PM

Oragenics Inc ( OGEN ) shares are trading lower by 45.5% to $0.58 during Wednesday’s session after the company announced a $4.45 million public offering of 8,106,584 shares at $0.55 per share.

The public offering is expected to close around September 5, pending standard closing conditions, and is anticipated to raise approximately $4.45 million before fees and expenses.

The funds will be used for the development of the company’s ONP-002 product and for general corporate purposes. Dawson James Securities, Inc. is the sole placement agent for the offering.

Read Also: July Job Openings Fall To 3-Year Lows, Gap With Unemployment Narrows To Near Parity: Traders Raise Rate Cut Bets

Should I Sell My OGEN Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of Oragenics ( OGEN ) have lost 82.44% year to date. This compares to the average annual return of -70.43%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

OGEN has a 52-week high of $7.74 and a 52-week low of $0.54.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lumentum Fiscal Q1 Adjusted Earnings, Revenue Rise; Issues Q2 Outlook
Lumentum Fiscal Q1 Adjusted Earnings, Revenue Rise; Issues Q2 Outlook
Nov 4, 2025
04:38 PM EST, 11/04/2025 (MT Newswires) -- Lumentum ( LITE ) reported fiscal Q1 adjusted earnings Tuesday of $1.10 per diluted share, compared with $0.18 a year earlier. Analysts polled by FactSet expected $1.03. Net revenue for the quarter ended Sept. 27 was $533.8 million, up from $336.9 million a year earlier. Analysts surveyed by FactSet expected $526.5 million. The...
Assurant Q3 adjusted EPS beats estimates, helped by global housing growth
Assurant Q3 adjusted EPS beats estimates, helped by global housing growth
Nov 4, 2025
Overview * Assurant ( AIZ ) Q3 adjusted EPS beats analyst expectations, rising 91% yr/yr * Adjusted EBITDA for Q3 rises 75% yr/yr due to lower reportable catastrophes * Company increases 2025 outlook, expects low double-digit adj EPS growth excluding reportable catastrophes Outlook * Assurant ( AIZ ) expects 2025 adjusted EPS to grow low double-digits, excluding reportable catastrophes *...
Specialty chemicals firm Ascent Industries Q3 gross profit jumps on efficient cost management
Specialty chemicals firm Ascent Industries Q3 gross profit jumps on efficient cost management
Nov 4, 2025
Overview * Ascent Industries ( ACNT ) Q3 gross profit nearly doubles yr/yr, driven by cost management * Company reports Q3 adjusted EBITDA of $1.4 mln, reflecting improved operational performance * Net sales for Q3 declined 5.7% yr/yr due to lower volume, partially offset by higher prices Outlook * Company did not provide specific guidance for future quarters in its...
Irish biopharma firm Avadel's Q3 revenue up 55%, but net income misses estimates
Irish biopharma firm Avadel's Q3 revenue up 55%, but net income misses estimates
Nov 4, 2025
Overview * Avadel Q3 net product revenue rises 55% yr/yr to $77.5 mln * However, net income for missed analysts' expectations as costs rose sharply Outlook * Company expects Alkermes acquisition to close in Q1 2026 * Avadel progressing REVITALYZ trial for LUMRYZ, completion expected by end of 2025 * Settlement with Jazz allows LUMRYZ commercialization beyond narcolepsy from March...
Copyright 2023-2026 - www.financetom.com All Rights Reserved